MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
调节灵长类动物的淋巴毒素以防御病毒
基本信息
- 批准号:8357268
- 负责人:
- 金额:$ 19.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAgonistAntiviral AgentsCaliforniaCardiovascular DiseasesCessation of lifeChronicClinicalCytomegalovirusCytomegalovirus InfectionsDataEquilibriumFc ReceptorFundingGoalsGrantHerpesviridaeHost DefenseImmuneImmunocompetentImmunocompromised HostImmunotherapeutic agentIn VitroInfectionInflammationLymphocyteLymphoid TissueMacacaMacaca mulattaMaintenanceModelingMurid herpesvirus 1MusNational Center for Research ResourcesPathway interactionsPatientsPlayPrimatesPrincipal InvestigatorReagentReceptor SignalingResearchResearch InfrastructureResourcesSignal PathwaySourceSystemTestingTimeToxic effectTumor Necrosis Factor-BetaTumor Necrosis Factor-alphaUnited States National Institutes of HealthViralVirusVirus DiseasesVirus Replicationchemotherapycostcytokineeffective therapyefficacy testingin vivomembernovelnovel strategiespathogenpreventreceptorresearch studysuccessviral resistance
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Cytokine members of the Tumor Necrosis Factor (TNF) Superfamily play key roles in host defense to viral pathogens. In particular, the Lymphotoxin (LT)alpha-beta-LTbeta receptor (LTbetaR) system and other closely related cytokines are required for effective immune defenses against cytomegalovirus (CMV), a beta herpes virus. Both in vitro studies with human CMV and in vivo studies with murine CMV indicate that the LTbetaR system plays a key role in the establishment and maintenance of immunological balance between the host and this persistent virus. Specifically, in vivo activation of the LTbetaR by an agonist anti-LTbetaR antibody can prevent lymphocyte death, restore IFNbeta levels, reorganize lymphoid tissue and extend the survival of MCMV infected, LTalpha-deficient mice. These results indicate that modulating the LTbetaR pathway in vivo can restore immune balance during this viral infection. Human CMV infection remains a stubborn clinical problem especially in immune compromised (chemotherapy or AIDS) patients, and emerging evidence suggests chronic inflammation, associated with persistent viruses like HCMV, may also contribute to cardiovascular disease. Clinically, there exists a particular need for effective treatment of this virus since the efficacy of antiviral drugs has been limited by toxicity and viral resistance. Understanding the limitations of currently available anti-viral treatment provides strong impetus to identify novel approaches that will enhance the host's immune responsiveness while at the same time effectively suppressing virus replication. The goal of this proposal is to test the hypothesis that the LTbetaR is a significant factor in host defense to human CMV. To accomplish this 3 specific aims are proposed to investigate the LT cytokine system in a rhesus macaque primate model of CMV infection (RhCMV), a model which most closely resembles human CMV infection. In specific aim 1, the LTbetaR signaling pathway will be studied in vitro using agonistic and antagonistic reagents to provide mechanistic data for the in vivo studies proposed in specific aims 2 and 3. These in vivo experiments will directly test the efficacy of LT(R agonists and antagonists as modulators of RhCMV infection and in particular the ability of an agonist anti-LTbetaR antibody to ameliorate the infection in both immunocompetent and immunocompromised macaques. The success of this reagent in macaques should validate this novel immunotherapeutic approach as a potential treatment for human CMV infection.
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
肿瘤坏死因子超家族的细胞因子在宿主对病毒病原体的防御中起着关键作用。特别是,淋巴毒素(LT)α-β-LTbetaR(LTbetaR)系统和其他密切相关的细胞因子是有效免疫防御巨细胞病毒(CMV)所必需的。对人CMV的体外研究和对小鼠CMV的体内研究都表明,LTbetaR系统在建立和维持宿主和这种持久病毒之间的免疫平衡方面发挥着关键作用。具体地说,在体内,由激动剂抗LTbetaR抗体激活LTbetaR可以防止淋巴细胞死亡,恢复IFNβ水平,重组淋巴组织,并延长MCMV感染的LTalpha缺陷小鼠的生存时间。这些结果表明,在体内调节LTbetaR途径可以在病毒感染期间恢复免疫平衡。人类巨细胞病毒感染仍然是一个顽固的临床问题,特别是在免疫功能低下的(化疗或艾滋病)患者中,新出现的证据表明,与HCMV等持续病毒相关的慢性炎症也可能导致心血管疾病。在临床上,由于抗病毒药物的疗效受到毒性和病毒耐药性的限制,因此特别需要有效地治疗这种病毒。了解目前可用的抗病毒治疗的局限性,为寻找新的方法提供强大的动力,这些方法将增强宿主的免疫反应性,同时有效地抑制病毒复制。这一建议的目的是验证LTbetaR是宿主防御人类CMV的重要因素这一假设。为了实现这三个特定目标,我们提出了在巨细胞病毒感染猕猴灵长类动物模型(RhCMV)中研究LT细胞因子系统的建议,该模型最接近于人类CMV感染。在特定目标1中,将使用激动剂和拮抗剂在体外研究LTbetaR信号通路,为特定目标2和3中提出的体内研究提供机制数据。这些体内实验将直接测试LT(R激动剂和拮抗剂)作为RhCMV感染调节剂的有效性,特别是激动剂抗LTbetaR抗体改善免疫活性和免疫受损猕猴感染的能力。这种试剂在猕猴身上的成功应该验证这种新的免疫治疗方法作为一种潜在的人类巨细胞病毒感染的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl F Ware其他文献
RIGing a virus trap
设置病毒陷阱
- DOI:
10.1038/nm0905-929 - 发表时间:
2005-09-01 - 期刊:
- 影响因子:50.000
- 作者:
Chris A Benedict;Carl F Ware - 通讯作者:
Carl F Ware
Carl F Ware的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl F Ware', 18)}}的其他基金
Overriding the Immune Evasion Tactics of Coronavirus
推翻冠状病毒的免疫逃避策略
- 批准号:
10237419 - 财政年份:2020
- 资助金额:
$ 19.14万 - 项目类别:
Overriding the Immune Evasion Tactics of Coronavirus
推翻冠状病毒的免疫逃避策略
- 批准号:
10671613 - 财政年份:2020
- 资助金额:
$ 19.14万 - 项目类别:
Overriding the Immune Evasion Tactics of Coronavirus
推翻冠状病毒的免疫逃避策略
- 批准号:
10188930 - 财政年份:2020
- 资助金额:
$ 19.14万 - 项目类别:
Overriding the Immune Evasion Tactics of Coronavirus
推翻冠状病毒的免疫逃避策略
- 批准号:
10454292 - 财政年份:2020
- 资助金额:
$ 19.14万 - 项目类别:
MODULATING LYMPHOTOXINS IN PRIMATES FOR VIRAL DEFENSES
调节灵长类动物的淋巴毒素以防御病毒
- 批准号:
8172541 - 财政年份:2010
- 资助金额:
$ 19.14万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 19.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 19.14万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 19.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)